A multi-center, randomized, double-blind, placebo controlled study of the effect of SSR180575 at two doses for 24 weeks treatment on the rate of regeneration of epidermal nerve fibers in patients with mild diabetic peripheral neuropathy.

Trial Profile

A multi-center, randomized, double-blind, placebo controlled study of the effect of SSR180575 at two doses for 24 weeks treatment on the rate of regeneration of epidermal nerve fibers in patients with mild diabetic peripheral neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs SSR 180575 (Primary)
  • Indications Diabetic neuropathies
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Jan 2010 Planned number of patients changed from 270 to 309 as reported by ClinicalTrials.gov.
    • 16 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jul 2008 Additional trial identifier SSR180575 reoprted by ClinicalTrialls.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top